Alliance Profile
Alloy Therapeutics
IMA seeks to support translational research projects that will develop antibody prototypes by providing access to proprietary technologies from Alloy Therapeutics.
License Agreement
Stanford has obtained a worldwide, non-exclusive license to use the immunocompetent Alloy-Gx transgenic mice for in vivo human antibody discovery for research, development, and commercialization. This may include the following:
- immunizing ATX-Gx transgenic humanized mice
- isolating antibodies or cells that produce antibodies from the ATX-Gx mice
- cloning of the antibodies isolated from the ATX-Gx mice
- modification of the antibodies isolated from the ATX-Gx mice
- in vitro and in vivo characterization of the antibodies and modified antibodies
Introduction to Alloy Therapeutics
Alloy Therapeutic’s ATX-Gx platform is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery.
Alloy Gamma-Kappa (GK) Mouse:
A robust workhorse for in vivo antibody discovery and is the basis of the ATX-GX platform package:
- 10 years in development, originally invented and validated inside a major Pharma company then further developed at Alloy
- Complete functional human antibody repertoire – Gamma: 40+V, 23D, 6J Segments – Kappa: 19V, 5J Segments
- Fully functional immune system – robust immune response that is equivalent to wild type mice
- Available on multiple genetic backgrounds
ATX-GX mouse has been successful with a range of antigens.
Alloy is expanding the ATX-Gx strains:
- ATX-GK – MIX – incremental improvement to genetic background to optimize immunocompetence (available now)
- ATX-pGK and ATX-dGK – heavy chain repertoire split between two separate lines to overcome immunodominant germlines. Full kappa light chain diversity (in development)
- ATX-GL – generating human Lambda antibodies (available now)
Alloy is also creating new platforms:
The ATX-CLC platform for bispecific antibody discovery – a proprietary suite of common light chain mice, available for beta testing in 2021.
Contact
To learn how to access the Alloy Therapeutics platform, please contact:
Paul Humphries, Ph.D.
Alliance Director, Innovative Medicines Accelerator
phumphries@stanford.edu